The MarketWatch News Department was not involved in the creation of this content. HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best high growth healthcare stocks to buy now. Mizuho lifted the price ...

BridgeBio Pharma is back in focus after its fair value estimate was lifted from $89.79 to $100.05, an increase of about 11% that resets the conversation around upside and risk. That move aligns with ...

Through the collaboration, NJ Bio will integrate the AJICAP platform into its discovery and development workflows, offering clients a robust and highly reproducible approach for site-specific conjugat ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO International Convention from June 16-19 in Boston, where key executives, including CEO Georg Ng and President of R&D Dr.

The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition. The ...

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -34.05% and +2.77%, respectively, for the quarter ended ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO CEO & Investor Conference taking place on February 10-11, 2025, in New York City. The company's management will present a ...

This news release contains certain forward-looking statements relating to STARJEMZA ® /BAT2206 or the product pipelines in general of Bio-Thera Solutions and Hikma. Readers are strongly cautioned that ...

A claim has emerged that the pharmaceutical and bio-pharma industry could suffer annual losses of up to 3.6 trillion won if a policy to reduce generic drug prices to 40% of original drug prices is ...

LNK01006 reflects Lynk Pharmaceuticals' medicinal chemistry expertise, incorporating a highly optimized scaffold engineered for target selectivity, metabolic stability, and CNS penetration. "We are ...

NJ Bio, Inc. (NJ Bio), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma ...